Brief: Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005
24/02/2026 13:32
Feb 24 (Reuters) - Cadrenal Therapeutics Inc CVKD.O: CADRENAL THERAPEUTICS ANNOUNCES PHASE 2 RESULTS WITH ENCOURAGING REDUCTIONS IN THROMBOTIC EVENTS FOR CAD-1005 IN HIT, SUPPORTING CLINICAL ADVANCEMENT CADRENAL THERAPEUTICS INC: GRANTED END-OF-PHASE 2 MEETING WITH U.S. FDA TO ALIGN ON PHASE 3 REGISTRATION PATH Source text: ID:nGNX4xfjdB Further company coverage: CVKD.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology